Hanspeter Rottensteiner

Baxalta Innovations GmbH, Donau City Str. 7
Vienna, 1220, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.

Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.

Journal: Molecular therapy. Methods & clinical development
Published: August 30, 2024

Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.

Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.

Journal: Journal of thrombosis and haemostasis : JTH
Published: May 10, 2022

Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.

Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.

Journal: Haematologica
Published: October 26, 2021

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.

Journal: Molecular therapy. Methods & clinical development
Published: August 18, 2020

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector.

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector.

Journal: Molecular therapy. Methods & clinical development
Published: July 06, 2020

Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.

Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.

Journal: Molecular therapy. Methods & clinical development
Published: February 19, 2020

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.

Journal: Blood
Published: December 23, 2019

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Journal: The Journal of pharmacology and experimental therapeutics
Published: May 21, 2019

Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.

Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.

Journal: Journal of thrombosis and haemostasis : JTH
Published: March 26, 2019

Temperature-dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation.

Temperature-dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation.

Journal: Journal of thrombosis and haemostasis : JTH
Published: October 23, 2018

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.

Journal: Molecular therapy. Methods & clinical development
Published: March 12, 2018

Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.

Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH
Published: June 07, 2017
Showing 1-12 of 35

Last Updated: 09/26/2026